CDCorinna Dressler

Corinna Dressler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Corinna Dressler has a total of 162 co-authors. Here are the top co-authors by number of shared publications:

  • Alexander Nast

    Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin, Department of Dermatology, Venereology and Allergology Division of Evidence‐Based Medicine (dEBM Berlin Germany

    14 shared publications
  • Alexander Nast

    Division of Evidence-Based Medicine, Klinik für Dermatologie, Venerologie and Allergologie, Charité–Universitätsmedizin Berlin, Berlin, Germany

    6 shared publications
  • Ricardo Niklas Werner

    Department of Dermatology Venereology and Allergology Division of Evidence‐Based Medicine in Dermatology (dEBM) Charité – Universitätsmedizin Berlin corporate member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

    6 shared publications
  • Stefanie Rosumeck

    Institute for Quality Assurance and Transparency in Healthcare (IQTIG), Katharina-Heinroth-Ufer 1, 10787 Berlin, Germany

    6 shared publications
  • A. Torrelo

    Hospital Infantil Niño Jesús Madrid Spain

    2 shared publications
  • A.H. Fink‐Wagner

    Global Allergy and Airways Diseases Patient Platform GAAPP Vienna Austria

    2 shared publications

Latest Publications

  • Open Access

    Health Care Social Robots in the Age of Generative AI: Protocol for a Scoping Review

    by Paul Notger Lempe, Camille Guinemer, Daniel Fürstenau, Corinna Dressler, Felix Balzer, Thorsten Schaaf

    Background: Social robots (SR), sensorimotor machines designed to interact with humans, can help to respond to the increasing demands in the health care sector. To ensure the successful use of this technology, acceptance is paramount. Generative artificial intelligence (AI) is an emerging technology with the potential to enhance the functionality of SR and promote user acceptance by further improving human-robot interaction. Objective: We present a protocol for a scoping review of the literature on the implementation of generative AI in SR in the health care sector. The aim of this scoping review is to map out the intersection of SR and generative AI in the health care sector; to explore if generative AI is applied in SR in the health care sector; to outline which models of generative AI and SR are used for these implementations; and to explore whether user acceptance is reported as an outcome following these implementations. This scoping review supports future research by providing an overview of the state of connectedness of 2 emerging technologies and by mapping out research gaps. Methods: We follow the methodological framework developed by Arksey and O'Malley and the recommendations by the Joanna Briggs Institute. Our protocol was drafted using the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews). We will conduct a systematic literature search of the online databases MEDLINE, Embase, CINAHL (Cumulative Index to Nursing and Allied Health Literature), Web of Science, and IEEE Xplore, aiming to retrieve relevant data items via tabular data charting from references meeting specific inclusion criteria which are studies published from 2010 onwards, set in the health care sector, focusing on SR with physical bodies and implemented generative AI. There are no restrictions on study types. Results will be categorized, clustered, and summarized using tables, graphs, visual representations, and narratives. Results: After conducting a preliminary search and deduplication in the second quarter of 2024, we retrieved 3176 preliminary results. This scoping review will be supplemented with the next methodological steps, including retrieving the results in a reference management tool as well as screening titles, abstracts, and full text regarding specific inclusion criteria. The completion of these steps is scheduled for the second quarter of 2025. Limitations based on the heterogeneity of the included studies and the general breadth of a scoping review compared to a systematic review are to be expected. To reduce bias, we adopted a system of dual reviews and thorough documentation of the study selection. Conclusions: The conducted preliminary search implies that there are a sufficient number of heterogeneous references to complete this scoping review. To our knowledge, this is the first scoping review on generative AI in health care SR. International Registered Report Identifier (IRRID): PRR1-10.2196/63017


  • Open Access

    Guidance on how to efficiently find, choose, and use available systematic reviews was developed

    by Tim Mathes, Peggy Prien, Irma Klerings, Hannah Ewald, Corinna Dressler, Thomas Harder, Fülöp Scheibler, Roland Büchter, Cordula Braun, Kathrin Grummich, et al.


  • Open Access

    Health Care Social Robots in the Age of Generative AI: Protocol for a Scoping Review (Preprint)

    by Paul Notger Lempe, Camille Guinemer, Daniel Fürstenau, Corinna Dressler, Felix Balzer, Thorsten Schaaf

    BACKGROUND Social robots (SR), sensorimotor machines designed to interact with humans, can help to respond to the increasing demands in the health care sector. To ensure the successful use of this technology, acceptance is paramount. Generative artificial intelligence (AI) is an emerging technology with the potential to enhance the functionality of SR and promote user acceptance by further improving human-robot interaction. OBJECTIVE We present a protocol for a scoping review of the literature on the implementation of generative AI in SR in the health care sector. The aim of this scoping review is to map out the intersection of SR and generative AI in the health care sector; to explore if generative AI is applied in SR in the health care sector; to outline which models of generative AI and SR are used for these implementations; and to explore whether user acceptance is reported as an outcome following these implementations. This scoping review supports future research by providing an overview of the state of connectedness of 2 emerging technologies and by mapping out research gaps. METHODS We follow the methodological framework developed by Arksey and O'Malley and the recommendations by the Joanna Briggs Institute. Our protocol was drafted using the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-analyses extension for Scoping Reviews). We will conduct a systematic literature search of the online databases MEDLINE, Embase, CINAHL (Cumulative Index to Nursing and Allied Health Literature), Web of Science, and IEEE Xplore, aiming to retrieve relevant data items via tabular data charting from references meeting specific inclusion criteria which are studies published from 2010 onwards, set in the health care sector, focusing on SR with physical bodies and implemented generative AI. There are no restrictions on study types. Results will be categorized, clustered, and summarized using tables, graphs, visual representations, and narratives. RESULTS After conducting a preliminary search and deduplication in the second quarter of 2024, we retrieved 3176 preliminary results. This scoping review will be supplemented with the next methodological steps, including retrieving the results in a reference management tool as well as screening titles, abstracts, and full text regarding specific inclusion criteria. The completion of these steps is scheduled for the second quarter of 2025. Limitations based on the heterogeneity of the included studies and the general breadth of a scoping review compared to a systematic review are to be expected. To reduce bias, we adopted a system of dual reviews and thorough documentation of the study selection. CONCLUSIONS The conducted preliminary search implies that there are a sufficient number of heterogeneous references to complete this scoping review. To our knowledge, this is the first scoping review on generative AI in health care SR. INTERNATIONAL REGISTERED REPORT PRR1-10.2196/63017

  • Open Access

    3D bioprinting of liver models: A systematic scoping review of methods, bioinks, and reporting quality

    by Ahmed S.M. Ali, Dongwei Wu, Alexandra Bannach-Brown, Diyal Dhamrait, Johanna Berg, Beatrice Tolksdorf, Dajana Lichtenstein, Corinna Dressler, Albert Braeuning, Jens Kurreck, et al.


  • Top Cited Papers
    Open Access

    European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations

    by A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, G. Avila Valle, S. Barbarot, T. Bieber, H.A. Brough, P. Calzavara Pinton, S. Christen‐Zäch, et al.

    The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty‐nine experts (including clinicians and patient representatives) from 12 European countries participated. This second part of the guideline includes recommendations and detailed information on basic therapy with emollients and moisturizers, topical anti‐inflammatory treatment, antimicrobial and antipruritic treatment and UV phototherapy. Furthermore, this part of the guideline covers techniques for avoiding provocation factors, as well as dietary interventions, immunotherapy, complementary medicine and educational interventions for patients with atopic eczema and deals with occupational and psychodermatological aspects of the disease. It also contains guidance on treatment for paediatric and adolescent patients and pregnant or breastfeeding women, as well as considerations for patients who want to have a child. A chapter on the patient perspective is also provided. The first part of the guideline, published separately, contains recommendations and guidance on systemic treatment with conventional immunosuppressive drugs, biologics and janus kinase (JAK) inhibitors, as well as information on the scope and purpose of the guideline, and a section on guideline methodology.


  • Top Cited Papers
    Open Access

    European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy

    by A. Wollenberg, M. Kinberger, B. Arents, N. Aszodi, G. Avila Valle, S. Barbarot, T. Bieber, H.A. Brough, P. Calzavara Pinton, S. Christen‐Zäch, et al.

    The evidence‐ and consensus‐based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty‐nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients.


  • Open Access

    Methods Used for Indirect Comparisons of Systemic Treatments for Psoriasis. A Systematic Review

    by Alexander Nast, Corinna Dressler, Christopher Schuster, Daniel Saure, Matthias Augustin, Kristian Reich

    Background: Indirect comparisons (including network meta-analyses [NMAs]) allow us to compare benefits and risks of multiple interventions for the same clinical condition when head-to-head comparisons are not feasible. Objective: To provide guidance to the clinical community on better understanding indirect comparison methods to help them to interpret their results by applying two quality standards to published indirect comparisons of systemic biologics for moderate to severe psoriasis. Methods: A systematic literature review (SLR) of published indirect comparisons of biologics for the treatment of moderate to severe psoriasis in adults was conducted. Data extraction was performed using a predefined subset of NICE TSD7 (National Institute for Health and Care Excellence Technical Support Document 7) checklist questions and methods used to perform each analysis were descriptively compared. Methodological quality of the SLR underlying each indirect comparison was assessed using AMSTAR 2 (A MeaSurement Tool to Assess systematic Reviews version 2). Results: Twenty-two NMAs and four adjusted indirect comparisons (AICs) were identified. Although there were some similarities, for example, application of Bayesian random-effects models, several important methodological aspects varied considerably across NMAs identified, for example, classes of drugs, number of treatments and studies included, reporting and handling of different doses, and reporting of both checks for and investigations of inconsistency. Methodological comparisons across AICs were limited by the small number. The quality of most underlying SLRs described, assessed as overall level of confidence in the results, was ‘critically low’. Conclusions: Understanding that there are different methodologies employed to answer differing research questions is key to helping clinicians to interpret the indirect evidence currently available in psoriasis.


  • Top Cited Papers
    Open Access

    The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria

    by Torsten Zuberbier, Amir Hamzah Abdul Latiff, Mohamed Abuzakouk, Susan Aquilina, Riccardo Asero, Diane Baker, Barbara Ballmer‐Weber, Christine Bangert, Moshe Ben‐Shoshan, Jonathan A. Bernstein, et al.

    This update and revision of the international guideline for urticaria was developed following the methods recommended by Cochrane and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group. It is a joint initiative of the Dermatology Section of the European Academy of Allergology and Clinical Immunology (EAACI), the Global Allergy and Asthma European Network (GA²LEN) and its Urticaria and Angioedema Centers of Reference and Excellence (UCAREs and ACAREs), the European Dermatology Forum (EDF; EuroGuiDerm), and the Asia Pacific Association of Allergy, Asthma and Clinical Immunology with the participation of 64 delegates of 50 national and international societies and from 31 countries. The consensus conference was held on 3 December 2020. This guideline was acknowledged and accepted by the European Union of Medical Specialists (UEMS). Urticaria is a frequent, mast cell–driven disease that presents with wheals, angioedema, or both. The lifetime prevalence for acute urticaria is approximately 20%. Chronic spontaneous or inducible urticaria is disabling, impairs quality of life, and affects performance at work and school. This updated version of the international guideline for urticaria covers the definition and classification of urticaria and outlines expert‐guided and evidence‐based diagnostic and therapeutic approaches for the different subtypes of urticaria.